InsiderClue
Insiders · Profile

Dolan Matthew Vincent

EVP, Strategy & Corporate Dev at Dexcom. Filing since 15 Mar 2022. CIK 0001914994

Company
Date
Role
Action
Shares
Amount
Of holding
DXCM Dexcom
29 Jan 2025
EVP, Strategy & Corporate Dev
Sold at will
1,183
$102.82K
2.7%
DXCM Dexcom
15 May 2024
EVP Strategy and Corporate Dev
Sold on a plan
2,423
$306.70K
5.7%
DXCM Dexcom
15 Apr 2024
EVP Strategy and Corporate Dev
Sold on a plan
1,990
$274.24K
4.5%
DXCM Dexcom
15 Mar 2024
EVP Strategy & Corp Dev
Sold on a plan
4,203
$547.26K
8.7%
DXCM Dexcom
12 Mar 2024
EVP Strategy and Corporate
Sold at will
6,710
$901.90K
12.1%
DXCM Dexcom
1 Sep 2023
SVP Corporate Strategy-Develop
Sold at will
56
$5.73K
0.2%
DXCM Dexcom
16 Mar 2023
SVP Corporate Strategy-Develop
Sold, plan not stated
2,303
$264.85K
6.4%
DXCM Dexcom
13 Mar 2023
SVP Corporate Strategy-Develop
Sold, plan not stated
6,229
$661.96K
14.8%
DXCM Dexcom
6 Mar 2023
SVP Corporate Strategy-Develop
Sold, plan not stated
226
$25.85K
0.8%
DXCM Dexcom
1 Sep 2022
SVP Corporate Strategy-Develop
Sold, plan not stated
5
$408.15
0.0%
DXCM Dexcom
17 Mar 2022
SVP Corporate Development
Sold, plan not stated
484
$217.80K
6.8%
DXCM Dexcom
16 Mar 2022
SVP Corporate Development
Sold, plan not stated
686
$291.55K
8.8%
DXCM Dexcom
15 Mar 2022
SVP Corporate Development
Sold, plan not stated
1,016
$419.01K
11.5%
13 decisions on file.